We are live on ! Find out more
PBYI icon

Puma Biotechnology

119 hedge funds and large institutions have $893M invested in Puma Biotechnology in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 32

44% more call options, than puts

Call options by funds: $13.8M | Put options by funds: $9.56M

5.64% less ownership

Funds ownership: 99.26%93.61% (-5.6%)

11% less funds holding

Funds holding: 133119 (-14)

41% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 32

65% less capital invested

Capital invested by funds: $2.52B → $893M (-$1.63B)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
119
Holders Change
-14
Holders Change %
-10.53%
% of All Funds
3.16%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
19
Increased
49
Reduced
32
Closed
32
Calls
$13.8M
Puts
$9.56M
Net Calls
+$4.2M
Net Calls Change
-$30M

PBYI Hedge Fund Activity: Q1 2016 in Review

119 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2016, worth a combined $893M — down 65% from $2.52B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of PBYI and 19 opened new positions — a net loss of 13 holders — while 32 trimmed existing stakes and 49 added.

The largest buyer was Janus Henderson Investors US, adding an estimated $61.4M. The largest seller was Capital Research Global Investors, cutting an estimated $52M.

  • 119 institutional investors held Puma Biotechnology (PBYI) as of Q1 2016, down from 133 in Q4 2015.
  • Funds reported $893M of Puma Biotechnology stock for Q1 2016, down 65% quarter-over-quarter.
  • 19 funds opened new Puma Biotechnology positions in Q1 2016 and 32 closed out, a net change of -13 holders.
  • The largest Puma Biotechnology buyer in Q1 2016 was Janus Henderson Investors US, an estimated $61.4M added.
  • The largest Puma Biotechnology seller in Q1 2016 was Capital Research Global Investors, an estimated $52M sold.

Based on aggregated 13F filings for Q1 2016.